AZD3427 effects on renal perfusion in heart failure patients with reduced ejection fraction and renal impairment - Re-PERFUSE

Study identifier:D8330C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2024-513143-82-00

Will Be Recruiting

Official Title

A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)

Medical condition

Heart Failure with Reduced Ejection Fraction (HFrEF)

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Dopamine

Sex

All

Estimated Enrollment

12

Study type

Interventional

Age

20 Years - n/a

Date

Study Start Date: 17 Sept 2024
Estimated Primary Completion Date: 05 Sept 2025
Estimated Study Completion Date: 05 Sept 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Clinical Trial Consultants (CTC), Karolinska Institutet

Inclusion and exclusion criteria